Added to YB: 2025-05-05
Pitch date: 2025-04-30
REGN [neutral]
Regeneron Pharmaceuticals, Inc.
+26.23%
current return
Author Info
Notes From The Beauty Contest is a buy-side investor who thought it might be fun to write about stocks in their spare time and in their own way. Sign up for the newsletter.
Company Info
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Market Cap
$80.0B
Pitch Price
$587.27
Price Target
N/A
Dividend
0.45%
EV/EBITDA
14.60
P/E
18.76
EV/Sales
4.49
Sector
Biotechnology
Category
turnaround
Regeneron Pharmaceuticals, Inc. - $REGN
REGN (earnings update): Q1 weak - rev -3.7%, EPS -14%. Eylea franchise -26% (2mg -39%) due to reduced copay assistance funding affecting industry. REGN halting $400M+ charitable funding until Roche contributes. FDA CRL for Eylea-HD PFS (supplier issue). Pipeline strength: itepekimab (COPD, asthma), 9 siRNAs, NPR1 agonist.
Read full article (10 min)